# EDGAR Filing Document

**Accession Number:** 0001569340
**File Stem:** 0001493152-23-009987
**Filing Date:** 2023-3
**Character Count:** 7500
**Document Hash:** 25b658ce7f3dae9f783333b44b479cb4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-009987.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0001493152-23-009987

**CONFORMED SUBMISSION TYPE**: NT 10-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230331

**DATE AS OF CHANGE**: 20230331

**EFFECTIVENESS DATE**: 20230331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cell Source, Inc.
- **CENTRAL INDEX KEY:** 0001569340
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 320379665
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NT 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55413
- **FILM NUMBER:** 23783961

**BUSINESS ADDRESS:**
- **STREET 1:** 57 WEST 57TH STREET
- **STREET 2:** SUITE 400
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 646-612-7554

**MAIL ADDRESS:**
- **STREET 1:** 57 WEST 57TH STREET
- **STREET 2:** SUITE 400
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TICKET TO SEE, INC.
- **DATE OF NAME CHANGE:** 20130211

---

| | |
|:---|:---|
| **UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549**<br>**FORM 12b-25**<br>**NOTIFICATION OF LATE FILING** | OMB APPROVAL |
| **UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549**<br>**FORM 12b-25**<br>**NOTIFICATION OF LATE FILING** | OMB Number: 3235-0058<br> Expires: March 31, 2022<br> Estimated average burden hours<br> <u>per response 2.50</u> |
| **UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549**<br>**FORM 12b-25**<br>**NOTIFICATION OF LATE FILING** |  |
| **UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549**<br>**FORM 12b-25**<br>**NOTIFICATION OF LATE FILING** | SEC FILE NUMBER<br> 000-55413 |
| **UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549**<br>**FORM 12b-25**<br>**NOTIFICATION OF LATE FILING** |  |
| **UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549**<br>**FORM 12b-25**<br>**NOTIFICATION OF LATE FILING** | CUSIP NUMBER<br> 15114L104 |

---

*(Check one):* ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR

For Period Ended: December 31, 2022

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

☐ Transition Report on Form N-SAR

For the Transition Period Ended: _________________________________________

*Read Instruction (on back page) Before Preparing Form. Please Print or Type.*

**Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.**

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I — REGISTRANT INFORMATION**

Cell Source, Inc.

Full Name of Registrant

Former Name if Applicable

57 West 57<sup>th</sup> Street, Suite 400

Address of Principal Executive Office *(Street and Number)*

New York, New York 10019

City, State and Zip Code

---

| | |
|:---|:---|
| SEC 1344 (03-05) | **Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.** |

---

**PART II — RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

---

| | | |
|:---|:---|:---|
| ☒ | (a) | The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense |
| ☒ | (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
| ☒ | (c) | The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |

---

**PART III — NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

(Attach extra Sheets if Needed)

Cell Source, Inc. (the "Registrant") is unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the year ended December 31, 2022 (the "Annual Report") by the March 31, 2023 filing date applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Annual Report. As a result, the Registrant is still in the process of compiling required information to complete the Annual Report and its independent registered public accounting firm requires additional time to complete its review of the financial statements for the year ended December 31, 2022 to be incorporated in the Annual Report. The Registrant anticipates that it will file the Annual Report no later than the fifteenth calendar day following the prescribed filing date.

**PART IV — OTHER INFORMATION**

(1) Name and telephone number
 of person to contact in regard to this notification

<u>Itamar Shimrat</u> <u>(646)</u> <u>416-7896</u> <br> (Name) (Area Code) (Telephone Number)

(2) Have
 all other periodic reports required under Section 13 or 15(d) of the Securities Exchange
 Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months
 or for such shorter period that the registrant was required to file such report(s) been filed
 ? If answer is no, identify report(s). ☒ Yes ☐ No

(3) Is
 it anticipated that any significant change in results of operations from the corresponding
 period for the last fiscal year will be reflected by the earnings sttements to be included
 in the subject report or portion thereof ? ☐ Yes ☒ No If
 so, attach an explanation of the anticipated change, both narratively and quantitatively,
 and, if appropriate, state the reasons why a reasonable estimate of the results cannot be
 made.

<u>Cell Source, Inc.</u>

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: March 31, 2023 | By: | */s/ Itamar Shimrat* |
|  |  | Itamar Shimrat, Chief Executive Officer |

---

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

**ATTENTION**

**Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).**